28 February 2024 in Tropical Medicine & International Health
Objectives: Nipah and Hendra are deadly zoonotic diseases with pandemic potential. To date, no human vaccine or monoclonal antibody (mAb) has been licensed to prevent disease caused by these pathogens. The aim of this scoping review was to identify and describe all Phase I, II, and III clinical trials of vaccine candidates or mAbs candidates designed to prevent Nipah and Hendra in humans and to compare the characteristics of the vaccine candidates to characteristics outlined in the Target Product Profile drafted by the World Health Organisation as part of the WHO Research & Development Blueprint for Action to Prevent Epidemics.Methods: We searched 23 clinical trial registries, the Cochrane Central Register of Clinical Trials, and grey literature up to June 2023 to identify vaccine and mAb candidates being evaluated in registered clinical trials. Vaccine candidate and trial characteristics were double‐extracted for evaluation and the vaccine candidate characteristics were compared with the preferred and critical criteria of the World Health Organisation's Target Product Profile for Nipah virus vaccine.Results: Three vaccine candidates (Hendra Virus Soluble Glycoprotein Vaccine [HeV‐sG‐V], PHV02, and mRNA‐1215) and one mAb (m102.4) had a registered human clinical trial by June 2023. All trials were phase 1, dose‐ranging trials taking place in the United States of America or Australia and enrolling healthy adults. Although all vaccine candidates meet the dose regimen and route of administration criteria of the Target Product Profile, other criteria such as measures of efficacy and reactogenicity will need to be evaluated in the future as evidence becomes available.Conclusion: Multiple vaccine candidates and one mAb candidate have reached the stage of human clinical trials and are reviewed here. Monitoring progress during evaluation of these candidates and candidates entering clinical trials in the future can help highlight many of the challenges that remain.
3 May 2022 in Journal of Global Health Reports
Background: Imbalances in global health authorship have previously been documented, but the extent of the problem has yet to be examined longitudinally across many journals. This paper investigates the gender (2002-2020) and geographic distribution (2014-2020) of authors publishing in peer-reviewed global health journals. We also examined the amount of global health research collaboration among different income groups and continents. Methods: This cohort study analyzes articles published in 46 peer-reviewed global health journals. Gender-API assigned genders to 190,809 individuals who authored a combined 33,854 articles. The country affiliations of authors were categorized by continent and World Bank income groups. Descriptive analyses were conducted to assess collaboration between first and last authors belonging to different World Bank income groups and continents. Findings: Women made up 39.3% of global health authors, and there was a statistically significant increase in the proportion of women authors between 2002 and 2020. The proportion of all global health authors who are women was highest in high income countries (45.9%) and lowest in low income countries (28.2%). Authors from middle income countries comprised of an increasing proportion of global health authors between 2014 and 2020. For articles with multiple authors, 16.0% and 24.1% have first and last authors from different income groups and continents, respectively. Conclusions: While women and LMIC researchers are increasingly represented in global health publications, authorship gaps continue to persist. More research on structural determinants is necessary to elucidate how we improve authorship equity and support underrepresented global health expertise.
21 October 2026 in World Journal of Surgery
JHJoAnna L. Hunter‐Squires
Background: The shortage of practitioners trained to provide essential surgical care remains among the most stubborn contributors to the global burden of disease, particularly in resource‐constrained settings where expert trainers are scarce. The Surgical Education Learners Forum (SELF) is a global community of practitioners working to develop cost‐effective, scalable, open‐access training modules that let clinicians anywhere learn, practice, and evaluate procedural skills independently. The key difference between a SELF training module and traditional procedural skills training is an integrated self‐administered skills assessment (SASA) framework. Through SASA, the learner receives formative feedback from a physical simulator while practicing the physical and psychomotor skills it is designed to teach. SASA helps learners confidently transfer their new skills directly into clinical practice. This is the fourth article in the SELF series. Methods: Participants in the 2023 SELF Symposium “Self‐Administered Skills Assessment” working session were tasked with creating expert recommendation guidelines for developers creating SASA for training modules. The group engaged with idea generation in two key areas: understanding the learner journey and creating developer‐recommended best practices followed by agreement on next steps. Results: The primary recommendation for developers was to create a sustainable platform with straightforward delivery. The session also called for developing and supporting a global SELF community of practice to meet the needs of learners and developers. Conclusions: The further development and testing of SASA is integral to the success of the SELF community moving forward. The community must prioritize increasing the depth and breadth of research studies on SASA approaches and techniques in SELF training modules.